Andrew Pincetic, PhD

Andrew Pincetic is director of the immuno-neurology team at Alector and leads a group of scientists developing therapies that target the immune system for the treatment of neurodegenerative diseases. Trained in biochemistry and immunology, he demonstrated how the immune system modulates the endo-lysosomal pathway to restrict infection with retroviruses. He has also described a general principle regulating the function of antibodies through engagement of Fc receptors on immune cells. Through this work, he identified a novel Fc mutation that mimics the anti-inflammatory activity of intravenous immunoglobulin. Nuvig Therapeutics has licensed this molecule and is currently in Phase 1 clinical trial for treatment of inflammatory disorders. At Alector, his team developed the company’s first immuno-oncology molecule targeting SIRPa, which was licensed to Innovent Biologics for development in China. His team is currently developing a molecule that targets the lysosomal pathway in immune cells as a potential therapy for Parkinson’s disease.